With over 35 nationalities and a range of backgrounds represented in our Benevolent team, we aim to build an inclusive environment where our people can bring their authentic selves to work, be respected for who they are and the exceptional work they do. We welcome and actively encourage applications from all sections of society and are committed to offering equal employment opportunities regardless of sex, race, religion or belief, ethnic or national origin, marital, domestic or civil partnership status, sexual orientation, gender identity, parental status, disability, age, citizenship, or any other basis. We see our diversity as an asset as we tackle challenging problems that bridge the gap between drug discovery and technology.
Benevolent is hiring for biological scientists with a background or demonstrable track record in applied bioinformatics or biology-driven data science in drug discovery. These individuals, depending on experience, will join a team providing overall scientific and applied drug discovery direction to the growing BenevolentAI drug discovery platform and approaches.
Primarily facing the early drug target identification space, these individuals will be responsible for engaging with disciplines across the company ensuring new developments meet the needs and requirements of drug discovery across multiple disease areas.
Based at our London offices you will work closely with a diverse range of experts in biological sciences, chemical sciences, clinical, commercialisation, artificial intelligence, deep/machine learning and informatics teams to enrich the expanding BenevolentAI drug discovery portfolio.
Additional Responsibilities
Nice to haves
We share a passion for being part of a mission that matters, and we are always looking for curious and collaborative people who share our values and want to be part of our journey. If that sounds like a fit for you, hit the apply button and join us.
BenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery and development company listed on the Euronext Amsterdam stock exchange. Through the combined capabilities of its AI platform, scientific expertise, and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform™ powers a growing in-house pipeline of 13 named drug programmes and over 10 exploratory programmes, and it maintains successful collaborations with AstraZeneca, as well as leading research and charitable institutions. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.
Head over to our Glassdoor page to learn about our benefits, culture and to find out what our team thinks about life at Benevolent. You can also find out more about us on LinkedIn and Twitter.
Our team will only contact you from the domain @benevolent.ai. If you receive a suspicious contact request, please email hello@benevolent.ai. Thank you.